Tag: atopic dermatitis

May 9, 2018

AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates

AnaptysBio (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, reported operating...
April 9, 2018

Menlo Therapeutics’ Phase 2 Trial Results in Massive Share Price Fall

Menlo Therapeutics announced that its drug candidate serlopitant showed no significant difference over the placebo to reduce atopic dermatitis.
April 9, 2018

Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis

Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with...
March 29, 2018

Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with...
March 27, 2018

AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline

AnaptysBio (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced...
March 15, 2018

Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Sienna Biopharmaceuticals (NASDAQ:SNNA) reported the Company’s financial results for the fourth quarter and full year of 2017. As quoted in the...
March 6, 2018

AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results

AnaptysBio (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported...